Furthermore, data regarding immunotherapy are overall suggesting a lack of efficacy among patients with NSCLC harboring actionable driver genetic alterations (with only clear exception for KRAS mutations), especially in those who were never smokers, without any evidence of additional benefit from combining immunotherapy with targeted therapy [76,90,91]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.